TecMed
- Company typePrivate
- Founded1995
- HeadquartersCheyenne, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
TecMed firmographics
Firmographics- Name
- TecMed
- Legal name
- TecMed, Inc.
- Website
- https://tecmed.com
- Company type
- Private
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
TecMed industry classification
Industry- Product category
- Medical Device Intellectual Property / Blood Glucose Monitoring
- NAICS
- Other Measuring and Controlling Device Manufacturing (334519), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451), Surgical and Medical Instrument Manufacturing (339112)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG)
- akta.pro secondary industries
- Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Blood Glucose Monitoring Devices (Consumer CGM & Smart Glucometers) (CRACAQAE)
Keywords
Where TecMed is headquartered
LocationHeadquarters
- HQ city
- Cheyenne
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TecMed business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations, Others
TecMed product offering
Product offeringCore offering
TecMed develops and commercializes patented optical measurement intellectual property (Sentinel IP) for automated, accurate, real-time blood glucose measurement. The proprietary technology is licensed and integrated into hospital surgical and critical care bedside monitoring, laboratory instrumentation, consumer home monitoring, and medical device products, delivering approximately +/- 6% accuracy across 30 human studies versus competitors at +/- 10% or above.
Product overview
TecMed offers a single unified product: its proprietary Sentinel IP blood glucose measurement technology. This patented optical measurement technology is designed for clinical patient blood glucose monitoring and consumer self-monitoring markets. The technology provides automated, accurate, and real-time blood glucose measurement exceeding industry standards and healthcare requirements. Applications include hospital surgical and critical care bedside monitoring, laboratory settings, and consumer home markets.
Differentiator
Problem solved
Functional benefit
Products and services
- Sentinel IP (Blood Glucose Measurement Technology) Proprietary patented optical measurement technology delivering automated, accurate, real-time blood glucose measurement at approximately +/- 6% accuracy across 30 blind and double-blind human studies, providing 40-50% greater accuracy than existing glucose measurement technologies. Designed for integration into clinical patient monitoring, hospital surgical and critical care bedside systems, laboratory instrumentation, and consumer home self-monitoring devices.
Quantifiable outcome
- 40-50% greater accuracy than existing glucose measurement technologies
- +3 more outcomes
Companies that use TecMed
Customer profileSegments3 records
Ideal customer profiles2 records
TecMed technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
TecMed partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- YpsomedcoreTecMed is acquiring Ypsomed's diabetes care business, including insulin pump development arm and subsidiaries, in a deal valued at approximately $512.9 million. This acquisition represents TecMed's strategic expansion into diabetes care technology, enabling the company to enter the insulin pump market while maintaining its focus on blood glucose measurement innovation.
Scale indicators3 records
Recent moves4 records
Expansion highlights4 records
TecMed competitors and assessment
Company assessmentDirect peers
- LifeScan: LifeScan (OneTouch) is a major blood glucose monitoring competitor with deep retail pharmacy presence, directly comparable to TecMed's consumer self-monitoring target market.
- Dexcom: Dexcom is the leading continuous glucose monitoring (CGM) company whose G6/G7 systems compete directly with TecMed's targeted optical BGM/CGM platform across clinical and consumer diabetes markets.
- Abbott Diabetes Care (FreeStyle Libre): Abbott's FreeStyle Libre is the dominant CGM globally and a direct competitor to TecMed's blood glucose measurement technology in both clinical and consumer segments.
- Medtronic Diabetes: Medtronic offers integrated insulin pumps combined with CGM sensors (MiniMed 780G), the same integrated diabetes care model TecMed is pursuing through the Ypsomed acquisition.
- Roche Diabetes Care: Roche Diabetes Care (Accu-Chek) is a long-established blood glucose monitoring competitor serving both clinical point-of-care and consumer self-monitoring markets where TecMed plans to compete.
- Ascensia Diabetes Care: Ascensia (Contour product line) is a direct BGM competitor with established global distribution in diabetes self-monitoring, the same consumer market TecMed targets with its optical measurement IP.
- Nova Biomedical: Nova Biomedical manufactures clinical point-of-care blood glucose analyzers for hospital and critical care settings — the exact clinical use case TecMed targets with its +6% accuracy optical platform.
- Insulet Corporation: Insulet (Omnipod) is a leading tubeless insulin pump maker; the Ypsomed diabetes care business TecMed acquired competes directly with Insulet in patch-pump diabetes delivery.
Emerging players
- EKF Diagnostics: EKF Diagnostics provides point-of-care blood glucose analyzers (QuikRead, Lactate Scout) for clinical settings; an emerging comparable in TecMed's clinical hospital/critical care target segment.
Others
- Ypsomed Holding: Ypsomed sold its diabetes care business to TecMed for $512.9M; Ypsomed itself continues as an injection/delivery systems manufacturer, providing ecosystem context for TecMed's newly acquired insulin pump arm.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks5 records
Key highlights6 records
Customer concentration
TecMed financial estimates
Financial estimateRevenue estimate
Valuation estimate
TecMed leadership team
Management profileNumber of profiles
Profiles14 records
TecMed funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TecMed M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TecMed
What does TecMed do?
TecMed develops and commercializes patented optical measurement intellectual property (Sentinel IP) for automated, accurate, real-time blood glucose measurement. The proprietary technology is licensed and integrated into hospital surgical and critical care bedside monitoring, laboratory instrumentation, consumer home monitoring, and medical device products, delivering approximately +/- 6% accuracy across 30 human studies versus competitors at +/- 10% or above.
Is TecMed a public or private company?
TecMed is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was TecMed founded?
TecMed was founded in 1995. It employs 1 to 10 people.
Where is TecMed based?
TecMed is headquartered in Cheyenne, United States, in the North America region.
Who are TecMed's main competitors?
Direct peers on record are LifeScan, Dexcom, Abbott Diabetes Care (FreeStyle Libre), Medtronic Diabetes, Roche Diabetes Care, Ascensia Diabetes Care, Nova Biomedical and Insulet Corporation. EKF Diagnostics is listed as an emerging player. Ypsomed Holding is listed as an others.
Does TecMed have an API?
No public API is recorded for TecMed.
What industry is TecMed in?
TecMed's product category is Medical Device Intellectual Property / Blood Glucose Monitoring. Its primary akta.pro industry code is HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips, with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 334519 and its SIC code is 3845.